In real world, Kaftrio seen to lower risk of CF liver disease progression
In people with cystic fibrosis (CF), treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor) may reduce the risk of CF-related liver disease (CFLD) progression, according to a real-world study in France. Rates of severe liver complications were significantly lower among people with CF who were followed during the period after Kaftrio …